Skip to main content
Premium Trial:

Request an Annual Quote

Biocept, Catalyst Pharmaceuticals Ink Deal for Liquid Biopsy Technology

NEW YORK (GenomeWeb) – Catalyst Pharmaceuticals has signed an agreement to use Biocept's Target Selector liquid biopsy platform to screen for cancer in patients enrolled in a clinical trial of its rare disease drug Firdapse (amifampridine phosphate).

Firdapse is currently approved in the EU to treat Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disease often associated with malignancies such as small cell lung cancer. Catalyst holds the drug's North American rights.

Under the terms of their deal, Catalyst will use the Target Selector platform to screen LEMS patients enrolled in an ongoing US Phase III trial of Firdapse for early signals of small cell lung cancer. Testing will be offered every six month for up to two years, at no cost to the patient.

Additional terms were not disclosed.

"About half of LEMS patients have an underlying cancer associated with their disease, and we understand that this can be a source of patient anxiety," Catalyst Chief Medical Officer Gary Ingenito said in a statement. "Therefore, we are taking the extra step to enable our patients to determine if they express circulating tumor cells, so that further assessment can be performed."

Biocept President and CEO Michael Nall added that the deal with Catalyst is expected to help further validate the clinical utility of Target Selector. In recent months, the company has formed a number of collaborations to evaluate the platform in cancer patients including ones with Columbia University, the University of Minnesota, and MedStar Georgetown University Hospital.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.